FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Portfolio Pulse from Benzinga Newsdesk
Agenus Inc. (NASDAQ:AGEN) will hold a Type B End-of-Phase 2 meeting with the FDA in July to discuss its BOT/BAL therapy for relapsed/refractory metastatic colorectal cancer. The meeting aims to expedite the development and support a future BLA submission.
May 16, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agenus Inc. will hold a Type B End-of-Phase 2 meeting with the FDA in July to discuss its BOT/BAL therapy for metastatic colorectal cancer, aiming to expedite development and support a future BLA submission.
The Type B End-of-Phase 2 meeting with the FDA is a significant step for Agenus' BOT/BAL therapy, potentially expediting its development and supporting a future BLA submission. This news is likely to positively impact AGEN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100